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Abstract Malfunction of mitochondrial complex I caused
by nuclear gene mutations causes early-onset neurodegener-
ative diseases. Previous work using cultured fibroblasts of
complex-I-deficient patients revealed elevated levels of
reactive oxygen species (ROS) and reductions in both total
Ca2+ content of the endoplasmic reticulum (ERCa) and
bradykinin(Bk)-induced increases in cytosolic and mitochon-
drial free Ca2+ ([Ca2+]C; [Ca
2+]M) and ATP ([ATP]C;
[ATP]M) concentration. Here, we determined the mitochon-
drial membrane potential (Δψ) in patient skin fibroblasts and
show significant correlations with cellular ROS levels and
ERCa, i.e., the less negative Δψ, the higher these levels
and the lower ERCa. Treatment with 6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (Trolox) normalized
Δψ and Bk-induced increases in [Ca2+]M and [ATP]M. These
effects were accompanied by an increase in ERCa and Bk-
induced increase in [Ca2+]C. Together, these results provide
evidence for an integral role of increased ROS levels in
complex I deficiency and point to the potential therapeutic
value of antioxidant treatment.
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Abbreviations
Δψ mitochondrial membrane potential
Bk bradykinin
CI complex I or NADH:ubiquinone
oxidoreductase
OXPHOS oxidative phosphorylation
ROS reactive oxygen species
TMRM tetramethyl rhodamine methyl ester
ER endoplasmic reticulum




cytosolic and mitochondrial free Ca2+
concentration
[ATP]M mitochondrial ATP concentration
Introduction
Mitochondria are double membrane-bound organelles that
do not only constitute the ‘cellular power plants’ but also
are crucially involved in survival, apoptosis, redox control,
Ca2+ homeostasis, and many metabolic and biosynthetic
pathways [1]. To fulfill these diverse functions, mitochon-
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dria require a highly negative membrane potential across
their inner membrane (∆ψ), which is maintained by the
action of the three proton pumps (complexes I, III, and IV)
of the electron transport chain. Together with F0/F1-ATP-
synthase (complex V), which uses the resulting electro-
chemical proton gradient to generate ATP, and complex II
of the electron transport chain, which oxidizes FADH2,
these proton pumps constitute part of the oxidative
phosphorylation (OXPHOS) system, which accounts for
the majority of cellular ATP production.
Complex I (EC 1.6.5.3) is the largest OXPHOS complex
and clinical presentations associated with its deficiency
(MIM 252010) are heterogeneous ranging from severe
multi-system diseases with neonatal death (e.g., Leigh
Disease) to isolated myopathies [2]. Complex I consists of
seven subunits encoded by the mitochondrial DNA and 38
by that of the nucleus [3]. As to the nuclear genome,
disease-causing mutations have been identified in the genes
of core subunits NDUFV1, NDUFV2, NDUFS1, NDUFS2,
NDUFS3, NDUFS7, and NDUFS8 [4–9], supernumerary
subunits NDUFS4, NDUFS6, NDUFA11, and NDUFA2
[10–13], and complex I assembly factors NDUFAF2,
NDUFAF1, and C6orf66 [14–16].
Detailed knowledge of the cytopathological consequen-
ces of complex I deficiency is prerequisite to understanding
the clinical presentations and their heterogeneity, and
developing therapeutic strategies [17]. To gain this knowl-
edge, we study skin fibroblasts from patients with muta-
tions in nuclear complex I genes. We demonstrated that
these mutations can be associated with a reduction in Ca2+
content of the endoplasmic reticulum (ERCa; [18, 19]).
Because OXPHOS depends on the electrochemical proton
gradient, the latter might be altered in patient cells, leading
to a reduced supply of ATP to ER Ca2+-pumps, thus
explaining the observed reduction in resting ERCa. In
agreement with this idea, we showed before that chronic
inhibition of complex I by rotenone reduced ∆ψ and
decreased ERCa in healthy fibroblasts [20]. We furthermore
showed that a reduction in ERCa was paralleled by
decreased amplitudes of the bradykinin (Bk)-induced
increases in [Ca2+]C, [Ca
2+]M, [ATP]C and [ATP]M [19].
Finally, we demonstrated that these aberrations were
accompanied by a decrease in the rate of cytosolic Ca2+
removal during the decay phase of the Bk-induced [Ca2+]C
transient [19]. Because Bk stimulates the release of Ca2+
from the ER into the cytosol from which Ca2+ is taken up
by mitochondria to stimulate the OXPHOS process, these
data suggest that the reduction in resting ERCa is respon-
sible for the decrease in Bk-stimulated mitochondrial ATP
production, which, in turn, results in a lower cytosolic Ca2+
removal rate. Evidence comes from experiments with, on
the one hand, an inhibitor of mitochondrial Na+–Ca2+
exchange, which was shown to normalize both the Bk-
induced increase in [ATP]M and the rate of cytosolic Ca
2+
removal in patient fibroblasts [18], and on the other hand a
mitochondrial Ca2+ buffer, which decreased both parame-
ters in fibroblasts of a healthy individual [21].
Apart from alterations in intracellular Ca2+ handling we
observed elevated levels of reactive oxygen species (ROS)
in fibroblasts of patients with a nuclear complex I gene
defect [22, 23]. Because elevated ROS levels have been
associated with a less negative ∆ψ [24, 25], and because a
less negative ∆ψ might decrease mitochondrial ATP-
dependent Ca2+ uptake by the ER (see above), we here
investigated the relationship between ∆ψ, elevated ROS
levels and ERCa in these patient fibroblasts.
Materials and methods
Cell lines
Fibroblasts were obtained following informed parental
consent and according to the relevant Institutional Review
Boards from skin biopsies of four healthy subjects and ten
patients in whom an isolated complex I deficiency was
confirmed in both muscle tissue and cultured fibroblasts
(Table 1). Activity measurements were performed as
described previously [26]. The activity of the complex was
normalized against that of cytochrome c oxidase, which was
in the control range, and expressed as percentage of the
lowest control (0.11 mU/mU cytochrome c oxidase; [26]).
All patients were negative with respect to mitochondrial
DNA alterations previously associated with complex I
deficiency. Fibroblasts were cultured in HEPES (25 mM)-
buffered M199 medium (Invitrogen) supplemented with 10%
(v/v) fetal calf serum, 5 mg/l Tween 20, 100 IU/ml penicillin
and 100 IU/ml streptomycin.
Fluorescence imaging of ∆ψ
∆ψ was measured by digital imaging microscopy of
fibroblasts loaded with tetramethyl rhodamine methyl ester
(TMRM) as described in detail before [27]. During
measurements, cells were maintained in a HEPES–Tris
medium (pH 7.4) containing 132 mM NaCl, 4.2 mM KCl,
5.5 mM D-glucose, 1 mM MgCl2, 1 mM CaCl2 and 10 mM
HEPES.
Luminescence monitoring of [Ca2+]M and [ATP]M
[Ca2+]M and [ATP]M were determined by luminometry of
fibroblasts transduced with a baculovirus encoding mito-
chondrial targeted forms of wild-type aequorin (mtAEQ)
and luciferase (mtLUC) as described previously [18, 19,
21]. During [ATP]M measurements, cells were superfused
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with HEPES/Tris medium containing 5 μM beetle luciferin
(Promega, Madison, WI). Prior to [Ca2+]M measurements,
mtAEQ was reconstituted with 5 μM native coelenterazine
(Promega) in serum-free M199 medium for 1 h at 37°C.
The wild-type aequorin-native coelenterazine pair measures
Ca2+ concentrations in the 0.1–10 µM range and mtAEQ
photon emission was converted off-line to Ca2+ concentra-
tion by using of a computer algorithm based on the Ca2+
response curve of wild-type aequorin [28]. Bk was added
through the superfusion medium.
Fluorescence imaging of [Ca2+]C
[Ca2+]C was measured by digital imaging microscopy of
fibroblasts loaded with fura-2 as previously described [18,
19, 21]. Bk, applied through the superfusion medium,
evoked a transient increase in fura-2 fluorescence emission
ratio. The rate of Ca2+ removal was determined by fitting
the decay phase of the transient to a mono-exponential
equation as described before [18, 19, 21].
Determination of ERCa
ERCa was determined by digital imaging microscopy of
fibroblasts loaded with fura-2 as described before [18, 19,
21]. Briefly, cells were challenged with 2′,5′-di(tert-butyl)-
1,4-benzohydroquinone (BHQ; 10 µM), a specific inhibitor
of the ER Ca2+ ATPase, in the absence of external Ca2+ (no
Ca2+ added to the extracellular medium and in the presence
of 0.5 mM EGTA). Under these conditions, Ca2+ that
passively leaks out of the ER is not resequestered, resulting
in a rapid increase in [Ca2+]C. The peak increase in
fluorescence emission ratio after treatment with BHQ was
used as a measure of ERCa.
Chemicals and statistics
Culture material and TMRM were from Invitrogen (Breda,
The Netherlands). Trolox was from Fluka (Buchs, Switzer-
land). All other reagents were from Sigma (Zwijndrecht, the
Netherlands). Values from multiple experiments were
expressed as average±S.E.M and statistical significances
were assessed by Student's t-test.
Results
∆ψ is reduced in complex-I-deficient patient fibroblasts Us-
ing our recently developed method for microscopic quan-
tification of ∆ψ in cultured human skin fibroblasts [13, 27,
Table 1 Characteristics of control and patient fibroblasts
Cell linea Mutation CI act.b Mean TMRM pixel intensityc ER Ca2+ contentd Rate of CM-DCF
formatione
Gene Protein
C-5120 None None 113 100±0.2 (N=1033) 100±1 (N=81) 100±2 (N=412)
C-4996 None None N.d. 100±0.7 (N=134) N.d. N.d.
C-5118 None None 103 99±0.7 (N=115) 102±8 (N=20) 125±13 (N=61)
C-5119 None None 105 99±1.1 (N=65) 102±6 (N=15) 100±11 (N=48)
S1-6173 NDUFS1 R557X/D618N 31 92±0.8 (N=120) 82±4 (N=29) 171±13 (N=87)
S2-5067 NDUFS2 P229Q 36 94±1.2 (N=105) 94±4 (N=70) 351±41 (N=28)
S2-5170 NDUFS2 R228Q 39 99±0.6 (N=126) 95±2 (N=23) 169±7 (N=124)
S4-4608 NDUFS4 K158fs 75 87±0.8 (N=112) 96±4 (N=44) 289±46 (N=29)
S4-5260 NDUFS4 R106X 36 92±0.9 (N=110) 77±4 (N=40) 187±12 (N=160)
S4-5737 NDUFS4 VPEEH167/VEKSIstop 53 95±0.6 (N=160) 87±6 (N=22) 202±12 (N=98)
S7-5175 NDUFS7 V122M 68 91±0.4 (N=384) 73±2 (N=16) 212±15 (N=76)
S8-6603 NDUFS8 R94C 18 89±0.8 (N=121) 85±6 (N=17) 275±20 (N=117)
V1-5866 NDUFV1 R59X/T423M 64 94±0.8 (N=68) 87±3 (N=43) 135±12 (N=49)
V1-5171 NDUFV1 R59X/T423M 73 92±1 (N=104) 96±3 (N=48) 242±19 (N=78)
Statistics: values significantly different from control C-5120 (p<0.05) are depicted in italics
N indicates the number of cells analyzed, N.d. not determined, C indicates control cells
a Numerals indicate the designation of the cell lines within the Nijmegen Center for Mitochondrial Disorders (NCMD)
bDetermined relative to complex IV and expressed as percentage of lowest control [35]
c Expressed as % of the value for control C-5120
d ERCa, expressed as % of the value for control C-5120 [23, 25]
e Expressed as % of the value for control C-5120 [27, 28]
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29], we here show that ∆ψ is variably decreased in
fibroblast lines of ten complex-I-deficient patients com-
pared to four healthy individuals (Fig. 1a). For each cell
line, the average TMRM intensity per mitochondrial pixel
is expressed relative to that of C-5120 healthy fibroblasts
measured on the same day. Linear regression analysis
revealed the absence of any correlation between ∆ψ and
residual complex I activity.
∆ψ is related to cellular ROS levels and ERCa We showed
previously that cellular ROS levels are elevated to a
variable extent in our whole cohort of complex-I-deficient
patients (Table 1; [22, 23]). Linear regression analysis
revealed a negative correlation between ROS levels and ∆ψ
(Fig. 1b). We have also shown that, similar to cellular ROS
levels, ERCa is variably decreased in these patient fibro-
blasts (Table 1; [19]). Again a significant, this time positive
correlation was observed (Fig. 1c).
Chronic Trolox treatment normalizes ∆ψ Based on the
significant correlation between ROS levels and ∆ψ, as
shown in Fig. 1b, we concluded that lowering of oxidant
levels may restore the electrochemical proton gradient
across the inner mitochondrial membrane. We previously
demonstrated that chronic treatment of patient fibroblasts
with Trolox, a water-soluble analogue of vitamin E,
reduced ROS levels and increased the amount of fully
assembled complex I [30]. Figure 2 shows that chronic
Trolox (300 µM, 72 h) fully restored ∆ψ in S4-5260 and
S7-5175 patient cells, which were among those displaying
the largest decrease in ∆ψ (Fig. 1a). Trolox did not affect
∆ψ in healthy fibroblasts.
Chronic Trolox treatment dose-dependently increases
ERCa A reduced ∆ψ may have severe consequences for
mitochondrial energy metabolism and thus for cellular
processes, such as ER Ca2+ uptake, that depend hereupon.
Fig. 1 Mitochondrial mem-
brane potential is reduced in
complex-I-deficient patient
fibroblasts and correlates with
cellular ROS levels and ER Ca2+
content. a Mean TMRM pixel
intensity in healthy and
complex-I-deficient human skin
fibroblasts. In each experiment,
the mean value obtained with
healthy control fibroblasts
(C-5120) was set at 100%, to
which all values were related.
Significant differences with
C-5120 are indicated by
*p<0.05 and ***p<0.001.
Error bars indicate SEM.
Numerals within bars indicate
the number of individual cells
analyzed. b Linear relationship
between mean TMRM pixel
intensity and cellular reactive
oxygen species (ROS) levels,
indicated by the rate of oxida-
tive formation of fluorescent
5-(and -6)-chloromethyl-2′,7′-
dichlorofluorescein (CM-DCF),
for fibroblast lines of three
healthy subjects (C-5120,
C-5118, C-5119; closed circles)
and ten patients (S7-5175,
S2-5170, S8-6603, S1-6173, S2-
5737, V1-5171, V1-5866,
S4-4608, S4-5260, S2-5067;
open circles). c Linear relation-
ship between mean TMRM pix-
el intensity and endoplasmic
reticulum Ca2+ content (ERCa).
CM-DCF and ERCa data were
taken from [19, 20, 23, 31]
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This prompted us to investigate the possibility that Trolox
may restore ERCa in our patient fibroblasts. Indeed, chronic
Trolox (72 h) dose-dependently increased ERCa to ∼135% of
the value obtained with untreated C-5120 healthy cells in
both these and S4-5260 patient fibroblasts (Fig. 3). The half-
maximal effect was reached at ∼85 µM Trolox. In sharp
contrast, acute application of Trolox (500 µM; 30 min)
neither changed ERCa in healthy (n=22 cells) nor increased it
in patient (n=21 cells) fibroblasts (data not shown). The S4-
5260 patient cell line was selected because it was among
those with the largest decrease in ∆ψ and ERCa.
Chronic Trolox treatment restores aberrant Ca2+ and ATP
handling during bradykinin stimulation In a final series of
experiments, we assessed the effect of chronic Trolox on
the Bk-induced increase in [Ca2+]C, the ensuing increases in
[Ca2+]M and [ATP]M and the rate of cytosolic Ca
2+
removal. Figure 4a shows that chronic Trolox dose-
dependently increased the amplitude of the Bk (1 µM)-
induced increase in [Ca2+]C to ∼125% of that in untreated
C-5120 healthy cells in both these and S4-5260 patient
cells. The half-time of Ca2+ removal (t1/2) decreased from
22.5±0.8 s (n=28 cells) and 14.6±0.6 s (n=28 cells) for
untreated and Trolox-treated patient fibroblasts, respective-
ly. This means that Trolox also normalized the slower
cytosolic Ca2+ removal rate in patient cells. Trolox did not alter t1/2 in healthy fibroblasts (t1/2=14.2±0.8 s and 14.5±
0.6 s for 24 untreated and 31 Trolox-treated healthy cells,
respectively).
Chronic Trolox did not affect the Bk-induced peak
increase in [Ca2+]M in healthy fibroblasts (Fig. 4b). In S4-
5260 patient cells, however, chronic Trolox dose-
dependently increased this parameter to the same value as
in untreated healthy cells. Chronic Trolox was also without
affect on the Bk-induced peak [ATP]M increase in healthy
cells, whereas it normalized this parameter in patient cells
(Fig. 4c).
Discussion
NADH:ubiquinone oxidoreductase or complex I forms a
major entry point of electrons into the mitochondrial
OXPHOS system and its malfunction is associated with a
wide variety of clinical presentations [2]. To understand the
cellular mechanisms underlying these syndromes, we study
cultured skin fibroblasts of a unique cohort of patients with
inherited complex I deficiency of nuclear origin [20, 31,
32]. One of our most striking findings is that the amount of
fully assembled complex I is markedly decreased in patient
fibroblasts, indicating that in addition to a likely decrease in
intrinsic catalytic activity also its assembly and/or stability
is compromised [22, 30, 32]. Other important findings
include increased ROS levels and disturbances of Ca2+ and
Fig. 2 Trolox treatment restores the mitochondrial membrane
potential in complex-I-deficient patient fibroblasts. Mean TMRM
pixel intensity in healthy (C-5120; black bars) and patient (S4-5260,
S7-5175; open bars) fibroblasts cultured for 72 h in the absence or
presence of Trolox (300 µM). In each experiment, the mean value
obtained with vehicle-treated healthy fibroblasts was set at 100%, to
which all values were related. (a) Significantly different from vehicle-
treated C-5120. (b) Significantly different from vehicle-treated S4-
5260. (c) Significantly different from vehicle-treated S7-5175. The
values presented are the mean±SEM of 100–200 individual cells ***
(p<0.001)
Fig. 3 Trolox treatment dose-dependently increases the ER Ca2+
content in complex-I-deficient patient fibroblasts and healthy fibro-
blasts. Endoplasmic reticulum Ca2+ content (ERCa) in healthy
(C-5120; black bars) and patient (S4-5260; open bars) fibroblasts
cultured for 72 h in the absence or presence of the indicated
concentration of Trolox. For each experimental condition, the values
presented are the average±SEM of 20–50 fibroblasts. (a) Significantly
different from vehicle-treated healthy fibroblasts. (b) Significantly
different from corresponding vehicle-treated patient fibroblasts ***(p<
0.001)
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ATP homeostasis both at rest and during stimulation [20,
31]. It is presently unknown how these changes are exactly
brought about in these patient fibroblasts.
Here, we show that ∆ψ is significantly reduced in our
cohort of patient fibroblast lines. At first glance, the most
likely explanation would be a decrease in proton transloca-
tion. However, the OXPHOS system is most probably not
working at its maximum capacity in resting fibroblasts and
may, therefore, very well be able to maintain ∆ψ even when
the maximum capacity of its first complex is decreased due
to a lower expression and/or decreased intrinsic catalytic
activity. Given the strong correlation between ROS levels
and ∆ψ, i.e., the higher these levels, the less negative ∆ψ, the
above finding could also be explained in that increased ROS
levels induce a proton leak [33]. The relevance of the
consequent ∆ψ decrease would be to try and prevent
excessive ROS production. We also show that ∆ψ and ERCa
are correlated, i.e., the less negative ∆ψ, the lower ERCa.
Because ∆ψ is an important determinant for the rate of
mitochondrial ATP production, this result is in agreement
with our idea that fueling of ER Ca2+-pumps with
mitochondrial ATP is reduced in resting patient fibroblasts.
Importantly, our previous results argue against the idea that
the reduction in ERCa is due to increased ROS-induced Ca
2+
leak [18].
The other major finding is that chronic Trolox normal-
izes ∆ψ in patient fibroblasts without affecting this
parameter in healthy cells. This result is consistent with
the above-described mechanism in which elevated ROS
levels cause an increase in mitochondrial proton leak.
Additional support comes from work demonstrating that
Trolox is an efficient inhibitor of such a proton leak [34].
Normalization of ∆ψ likely restores cellular processes that
are disturbed by its disease-associated reduction. Among
these processes, adequate delivery of mitochondrial ATP to
ER Ca2+-pumps is of crucial relevance. Strikingly, chronic
Trolox increased ERCa in both healthy and patient
fibroblasts. Although the increase in healthy cells was
unexpected in view of the lack of effect of chronic Trolox
on ∆ψ, it should be noted that the increase in ERCa
observed with 100 µM Trolox was much more pronounced
in patient cells, suggesting a dual mechanism involving
normalization of ∆ψ (only in patient cells) and modification
of a hitherto unknown process (both in healthy and patient
cells). Such a dual mechanism is consistent with the idea
that elevated ROS levels hamper proper fueling of ER
Ca2+-pumps primarily by their effect on ∆ψ. Future
research will reveal whether the ∆ψ-independent mecha-
nism involves a decrease in passive Ca2+ leak, an increase
in Ca2+ buffering capacity in the lumen of the ER and/or an
increase in glycolytic ATP-dependent Ca2+ uptake.
The present result that the effect of chronic Trolox on
ERCa was paralleled by a similar effect on the Bk-induced
increase in [Ca2+]C is consistent with the linear relation-
ship between both parameters in our cohort of patient
fibroblast lines [19]. Similar to our finding, Trolox
enhanced the bombesin-induced increase in [Ca2+]C in
skin fibroblasts of patients with genetic and non-genetic
forms of Alzheimer's disease [35]. Although chronic
Trolox markedly enhanced the Bk-induced increase in
[Ca2+]C in both healthy and patient fibroblasts, it did not
affect the consequent increase in [Ca2+]M in healthy cells,
whereas it dose-dependently normalized this parameter in
patient cells. Calibration of the mtAEQ signal revealed
that Bk increased [Ca2+]M to ∼4.5 µM [18, 19, 21],
whereas the maximum Ca2+ concentration that can be
measured is 10 µM [28]. Therefore, the results obtained
suggest that the capacity of mitochondria to take up Ca2+
Fig. 4 Trolox treatment restores Ca2+ and ATP handling in patient
fibroblasts. a Dose-dependence of the effect of Trolox treatment for
72 h on the Bk-induced increase in [Ca2+]C in healthy (C-5120; closed
bars) and patient (S4-5260; open bars) fibroblasts. b The same for
[Ca2+]M and c the same for [ATP]M. The values presented are the
mean±SEM of 20–30 cells (a) or five to 15 coverslips (b and c). For
each parameter, the mean value obtained with vehicle-treated healthy
fibroblasts was set at 100%, to which all values were related. (a)
Significantly different from vehicle-treated C-5120. (b) Significantly
different from corresponding vehicle-treated S4-5260 ***(p<0.001)
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is restricted to a maximum that is reached with 1 µM Bk
and cannot be exceeded even when the Bk-induced
increase in [Ca2+]C is further increased by the action of
Trolox. Additional evidence for restricted Ca2+ uptake
capacity was obtained in experiments with an inhibitor of
mitochondrial Na+–Ca2+ exchange. As expected, this
inhibitor, CGP-37157, did not alter the Bk-induced
increase in [Ca2+]C, whereas it normalized the Bk-
induced increase in [Ca2+]M in patient cells [18, 21].
Strikingly, CGP-37157 was without effect in healthy
control cells, which is in agreement with the idea that
1 µM Bk maximally increases [Ca2+]M in healthy
fibroblasts.
In agreement with the widely accepted notion that
hormone-induced increases in [Ca2+]M stimulate mitochon-
drial ATP production [20], we show that chronic Trolox can
normalize this process in patient fibroblasts without affecting
it in healthy fibroblasts. Chronic Trolox normalized the rate
of cytosolic Ca2+ removal during the decay phase of the Bk-
induced [Ca2+]C transient in patient fibroblasts without
affecting this parameter in healthy cells. The same observa-
tion was reached using CGP-37157 [18, 21], whereas the
opposite was observed with the mitochondrial Ca2+ buffer
Rhod-2 [21]. These results, together with the fact that the
Bk-induced increase in [ATP]M is tightly correlated with the
rate of cytosolic Ca2+ removal for the whole cohort of patient
fibroblasts [19], clearly link these two processes.
In conclusion, the present results support the idea that
fueling with mitochondrial ATP of cytosolic processes that
are stimulated by hormone-induced increases in [Ca2+]C,
such as exocytotic release of neurotransmitters in nerve
cells and contraction and relaxation of muscle cells, may be
hampered in complex I deficiency. It is these two cell types
that are among the most vulnerable in this disease [2].
However, the most important conclusion of this study is
that the aberrations in Ca2+-stimulated mitochondrial ATP
production and the consequences thereof, such as observed
in complex I deficiency, can be overcome with drugs that
normalize the stimulus-induced increase in [Ca2+]M by
either blocking mitochondrial Ca2+ export (CGP-37157) or
increasing mitochondrial Ca2+ uptake (Trolox). It remains
an important future task to translate this cellular informa-
tion to clinical practice. Because patients with inborn errors
of mitochondrial metabolism present with variable disease
onset and a broad range of clinical symptoms, disease-
adapted or even individualized treatment strategies might
be required. In this context, Trolox and CGP-37157
constitute interesting new candidates to be evaluated as
treatment options.
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